Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could spot hidden thyroid cancer

NCT ID NCT02856347

Diagnosis Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tracer and underwent PET/CT scans. The goal was to see if this method finds more true positive nodes, which could help doctors decide on further treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-DOPA (a radioactive tracer for PET scans)
What this could lead to
If successful, this could improve detection of residual medullary thyroid cancer, guiding more precise follow-up and treatment decisions.
What could go wrong
This is a small, early-stage study (24 participants) focused on imaging accuracy, not treatment. The tracer may not prove better than existing methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Mar 2017

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> or = 18 years. 2. Patient with medullary thyroid cancer (sporadic or hereditary form). 3. Patient treated by total thyroidectomy with uni or bi-lateral lymph node dissection (in the central and/or lateral neck compartment). 4. Patient with elevated thyrocalcitonin rate \> or = 150 pg/ml assessed within 6 weeks or more after surgery. 5. Patient with standard imaging assessment performed during 3 months before PET 18-FDOPA. 6. Standard imaging assessment including at least a cervical ultra-sound, a cervico-thoracic CT-scan and/or a cervico-thoraco-abdomino-pelvic CT-scan and a liver MRI. 7. Patient able to be followed at least 6 months after PET 18-FDOPA. 8. If women are breastfeeding, nursing should be discontinued during 24 hours after PET 18-FDOPA. 9. Patient must provide written informed consent prior to any specific procedure or assessment. 10. Patient must be affiliated to the French Social Security System. Exclusion Criteria: 1. Pregnant patient. 2. Post-operative radiotherapy initiated before PET 18-FDOPA. 3. Patient with PET 18-FDG performed within 24 hours before PET 18-FDOPA. 4. Participation in any other clinical trial for therapeutic use. 5. Patient with PET / CT-scan exam contra-indication. 6. Any serious and/or unstable pre-existing psychological, familial, geographic or social condition that could interfere with medical follow-up and compliance to study procedures. 7. Patient protected by law.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medullary thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary medullary thyroid gland carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medullary thyroid cancer

Contacts and locations

Locations

  • CHU Haut-Lévêque

    Bordeaux, France

  • CHU Limoges

    Limoges, France

  • CHU Timone

    Marseille, France

  • ICM Montpellier

    Montpellier, France

  • Institut Claudius Regaud

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.